Granules India Limited Reports Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2012
January 24, 2013 at 04:04 am EST
Share
Granules India Limited reported unaudited consolidated and standalone earnings results for the third quarter and nine months ended December 31, 2012. For the quarter, on consolidated basis, the company reported net sales of INR 1,952.201 million against INR 1,857.227 million a year ago. Profit from operations before other income, interest and exceptional items was INR 128.586 million against INR 158.696 million a year ago. Profit from ordinary activities before tax was INR 86.356 million against INR 110.428 million a year ago. Net profit was INR 58.050 million or INR 2.80 per diluted share against INR 79.858 million or INR 3.96 per diluted share a year ago. EBITDA was INR 192 million, an increase of 12% compared to INR 212 million a year ago.
For the nine months, on consolidated basis, the company reported net sales of INR 5,599.897 million against INR 4,658.754 million a year ago. Profit from operations before other income, interest and exceptional items was INR 406.637 million against INR 307.239 million a year ago. Profit from ordinary activities before tax was INR 282.262 million against INR 194.277 million a year ago. Net profit was INR 201.546 million or INR 9.74 per diluted share against INR 135.745 million or INR 6.74 per diluted share a year ago. EBITDA was INR 593 million, an increase of 26% compared to INR 470 million a year ago.
For the quarter, on standalone basis, the company reported net sales of INR 1,739.569 million against INR 1,555.609 million a year ago. Profit from operations before other income, interest and exceptional items was INR 118.926 million against INR 136.153 million a year ago. Profit from ordinary activities before tax was INR 78.021 million against INR 89.450 million a year ago. Net profit was INR 54.290 million or INR 2.62 per diluted share against INR 59.581 million or INR 2.96 per diluted share a year ago.
For the nine months, on standalone basis, the company reported net sales of INR 5,008.466 million against INR 3,972.544 million a year ago. Profit from operations before other income, interest and exceptional items was INR 392.806 million against INR 288.970 million a year ago. Profit from ordinary activities before tax was INR 274.003 million against INR 183.806 million a year ago. Net profit was INR 190.939 million or INR 9.22 per diluted share against INR 125.235 million or INR 6.22 per diluted share a year ago.
Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceuticalâs products segment. Its geographical segments include within India and outside India. The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies Paracetamol, Metformin, Guaifenesin, and Methocarbamol APIs. It has over seven manufacturing facilities, approximately six of which are located in India and one in the United States. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. The Companyâs wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.
GRANULES INDIA LIMITED 
